Equillium posts new preclinical EQ504 data in ulcerative colitis at International AHR Conference

EQ•2026-09-29

Equillium disclosed preclinical EQ504 findings pointing to improved intestinal barrier repair, reduced inflammatory signaling and immune rebalancing in ulcerative colitis ahead of two poster presentations scheduled for September 29 to October 2, 2026.

Equillium posts new preclinical EQ504 data in ulcerative colitis at International AHR Conference

1. Preclinical findings

Related News

Farmer Mac farmland price index falls 6% in Q2 2025 to $7,592 per acre

Morgan Stanley Direct Lending Fund director Kevin Shannon resigns

Teradyne declares dividend of R$ 0.0254650390 per unit for BRT2ERBDR006, payable Oct. 1

Pyxis Oncology falls after launching equity offering

Salesforce signs deal to buy AI customer research platform Listen Labs